Dr Philip Sutton - V.P. of Translational Sciences
Released
Released
Announcement PDF
ASX Announcement
Appointment of Dr Philip Sutton as
Vice President of Translational Sciences
SYDNEY Australia, 11 July 2022: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the
Company), the Company developing a New Class of Synthetic Anti-infectives, is pleased
to announce the appointment of Dr Philip Sutton as Vice President of Translational
Sciences.
Dr Sutton joined Recce’s Scientific Advisory Committee 21st August 2020 whilst leading the
Mucosal Immunology Group at Murdoch Children’s Research Institute, investigating the
potential of Recce’s anti-infectives across a suite of pre-clinical programs. He also served
as the former Head of Immunology at CSL Limited in Melbourne, and has co-authored 99
peer-reviewed publications as well as Chief Editor of ‘Helicobacter pylori in the 21st
Century’.
Joining the Company on a full-time basis, Dr Sutton will take a leading role advancing
Recce’s compounds across a portfolio of infectious disease programs focussed on
significant unmet medical needs.
Recce Pharmaceuticals Chief Executive Officer James Graham said, “Dr Sutton joins
us at an exciting time as our clinical programs continue to advance and welcome his
contributions to the pipeline development of our new class of anti-infectives.”
Dr Sutton said, “I am delighted to join the Recce team and look forward to the time ahead in
addressing the global health problem of antibiotic-resistant superbugs and emerging viral
pathogens.”
This announcement has been approved for release by Recce Pharmaceuticals Board.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives
designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral
pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives:
RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and
potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their
superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for
viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to
overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating
Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity
post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts
Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug
candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical
testing required to fully evaluate safety and efficacy.
Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s antiinfective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet
medical needs.
Share your feedback
Discover